ImmunoGen (IMGN) Q4 results:
Revenues: $44.9M (+235.1%).
Net Income: $4.8M (+111.5%); EPS: $0.03 (+110.7%); Quick Assets: $176.2M (-32.8%).
2020 guidance: Revenues: $60M – 65M.
Anticipated 2020 events: Present initial data from
the Phase 1b FORWARD II platinum-agnostic doublet cohort evaluating
mirvetuximab in combination with Avastin (bevacizumab) in mid-2020.
File IND for IMGC936 in H1 2020.
Transition next generation anti-folate receptor alpha (FRĪ±) ADC, IMGN151, to pre-clinical development in mid-2020.
Shares are up 16% premarket.
Previously: ImmunoGen EPS beats by $0.08, beats on revenue (Feb. 14)
https://seekingalpha.com/news/3542200-immunogenplus-16-premarket-on-q4-beat-revenues-up-235
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.